
PEPG
PepGen Stock Soars 93% on Positive Data From Phase 2 Myotonic Dystrophy Trial
The biotech reported 46.5% mean splicing correction at the 10 mg/kg dose alongside its third-quarter results, with no serious adverse events reported.
PepGen Inc. · Nasdaq · Pharmaceutical Preparations

The biotech reported 46.5% mean splicing correction at the 10 mg/kg dose alongside its third-quarter results, with no serious adverse events reported.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedPepGen Q3 2026 net loss $19.4 million, $(0.28) per share, vs $(0.27) consensus; positive 10 mg/kg FREEDOM2-DM1 data announced alongside results
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits